Link to Original Source
Slashdot videos: Now with more Slashdot!
Link to Original Source
From TFA, 'Leon Lederman
www.operatingthetan.com for more information"
Quoting from http://www.depmed.ualberta.ca/dca/
DCA is an odourless, colourless, inexpensive, relatively non-toxic, small molecule. And researchers at the University of Alberta believe it may soon be used as an effective treatment for many forms of cancer.
Dr. Evangelos Michelakis, a professor at the U of A Department of Medicine, has shown that dichloroacetate (DCA) causes regression in several cancers, including lung, breast, and brain tumors.
Michelakis and his colleagues, including post-doctoral fellow Dr. Sebastian Bonnet, have published the results of their research in the journal Cancer Cell.
Scientists and doctors have used DCA for decades to treat children with inborn errors of metabolism due to mitochondrial diseases. Mitochondria, the energy producing units in cells, have been connected with cancer since the 1930s, when researchers first noticed that these organelles dysfunction when cancer is present.
Until recently, researchers believed that cancer-affected mitochondria are permanently damaged and that this damage is the result, not the cause, of the cancer. But Michelakis, a cardiologist, questioned this belief and began testing DCA, which activates a critical mitochondrial enzyme, as a way to "revive" cancer-affected mitochondria.
The results astounded him.
Michelakis and his colleagues found that DCA normalized the mitochondrial function in many cancers, showing that their function was actively suppressed by the cancer but was not permanently damaged by it.
More importantly, they found that the normalization of mitochondrial function resulted in a significant decrease in tumor growth both in test tubes and in animal models. Also, they noted that DCA, unlike most currently used chemotherapies, did not have any effects on normal, non-cancerous tissues.
"I think DCA can be selective for cancer because it attacks a fundamental process in cancer development that is unique to cancer cells," Michelakis said. "One of the really exciting things about this compound is that it might be able to treat many different forms of cancer".
Another encouraging thing about DCA is that, being so small, it is easily absorbed in the body, and, after oral intake, it can reach areas in the body that other drugs cannot, making it possible to treat brain cancers, for example.
Also, because DCA has been used in both healthy people and sick patients with mitochondrial diseases, researchers already know that it is a relatively non-toxic molecule that can be immediately tested patients with cancer."
From the article: When entering the site, some users have reported receiving a warning from Windows Live OneCare advising that the www.itsnotcheating.com.au site is a suspicious website.
The warning reads: "Phishing filter has determined this might be a phishing website. We recommend that you do not give any of your information to such websites. Phishing websites impersonate trustworthy websites for the purpose of obtaining your personal or financial information."
A Microsoft spokesperson said the company was unaware of the warning but pledged to amend it as soon as possible."
Here is the introductory paragraph from the statement:
We at Registerfly.Com would like to offer our sincere apologies to all that have been affected by the actions of our former CEO / President, Kevin Medina. We cannot change the past but will make every effort to change the future of RegisterFly.com. As a result of Mr. Medina's actions many of you have lost your domains, experienced problems with your Hosting, Renewals and Registrations. For this reason Mr. Medina's our "Board of Directors" had no recourse but to take action against Mr. Medina and fire him.
Clearly the remaining principles are placing 100% of the blame on Mr. Medina's shoulders, however this only leads to further questions: If Mr. Medina was locked out of the servers as of Monday, why is RegisterFly still having problems regaining control of their network? Why did they not fire Mr. Medina and address customer support issues sooner? Why did it take a threat from ICANN to motivate them to respond? When do they expect to give customers control over their domains once again? What will they do to regain customer domains they have already lost?"
However, among the incurably sick there is often a desperate desire to try anything — even an experimental cure — that promises some relief or the distant prospect of cure. Patient groups and the Internet are helping to put these sufferers in touch with researchers, but formal channels are few and far between.
Volterys (www.volterys.org) is the brain-child of Dr. Laurent Hermoye, a Belgian researcher who specialises in magnetic resonance imaging of the brain. His goal is to increase public awareness of the important role of the volunteers in clinical research and to facilitate contacts between volunteers and medical researchers. The legal and ethical aspects of arranging these introductions are in the hands of legal specialists, de Wolf & Partners who are party to the initiative.
It is a unique concept. volunteers sign up, free of charge, filling in a medical questionnaire which is anonymous but traceable. The researchers interrogate the database of anonymous volunteers to match them to the inclusion criteria of their trials. It is not dissimilar to on-line contact dating! The two sides are only put in direct touch with each other when a match has been made and the two parties have agreed upon a specific research project. The recruitment is managed by the researcher's laboratory and conforms to the ethical guidelines laid down by the Helsinki declaration and the European directive of 4 April 2001.
Volterys volunteers have a unique opportunity to contribute to the advance of medical knowledge and also benefit from new treatments before they are available to the public at large. For some studies there is monetary reward. Researchers who avail themselves of the service reduce the time and effort entailed in the cumbersome business of enrolment of adequate numbers of subjects for meaningful clinical trials, all for a very reasonable fee. Volterys offers a free service to researchers doing work on so-called 'orphan drugs' or treatments for rare diseases, where recruiting suitable volunteers is even more difficult.
In the 9 months since the website was launched in France and Belgium, more than 9.000 volunteers have registered. Volterys is now extending its service to Europe and hopes eventually to expand throughout the world."